10 completed, 1 terminated, 1 unknown. 12 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 10, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
Follow Pupil Disorders: new trials by email Literature Review of Pupil Disorders trials Research Report on Pupil Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Efficacy and Safety of CTO0303 in Pediatric Subjects CTO0303-A, CTO0303-B, CTO0303-C - Pupillary Dilation Effect During Cycloplegic Refraction | Phase 2 / Phase 3 | Unknown | Taejoon Pharmaceutical Co., Ltd. | 156 | 2024-05-09 | 2024-09-24 |
| Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Placebo (Vehicle) ophthalmic solution - Presbyopia, Near Vision | Phase 3 | Completed | Corxel Pharmaceuticals | 300 | 2023-09-27 | 2025-03-03 |
| Pupillary Unrest as an Indicator of Central Opioid Effect in Subjects 40-60 Years of Age Remifentanil Hydrochloride, Pupillometry measurement - Opioid Toxicity, Pupillary Miosis | Phase 2 / Phase 3 | Completed | University of California, San Francisco | 10 | 2022-10-01 | 2025-05-02 |
| Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle - Mydriasis, Dilation | Phase 3 | Completed | Opus Genetics, Inc | 23 | 2021-12-17 | 2026-10-30 |
| Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3) Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle - Mydriasis, Dilation | Phase 3 | Completed | Opus Genetics, Inc | 368 | 2021-11-18 | 2026-10-30 |
| Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle (Placebo) - Mydriasis, Dilation | Phase 3 | Completed | Opus Genetics, Inc | 185 | 2020-11-18 | 2026-10-30 |
| Effect of Intracameral Injection of Mydriatic Plus Anaesthetic Combination on Corneal Endothelial Count in Phaco Fydrane®: (Manufacturer DELPHARM TOURS, FRANCE). - Corneal Endothelial Cell Loss, Mydriasis | Phase 3 | Completed | Cairo University | 30 | 2019-02-01 | 2020-05-20 |
| Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation Tropicamide/Phenylephrine ophthalmic solution (TR/PE), Placebo - Mydriasis | Phase 3 | Completed | Eyenovia Inc. | 76 | 2018-12-01 | 2022-03-18 |
| Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE), Tropicamide 1% ophthalmic solution (TR), Phenylephrine 2.5% ophthalmic solution (PE) - Mydriasis | Phase 3 | Completed | Eyenovia Inc. | 70 | 2018-11-15 | 2022-03-18 |
| Topical 0.4% Ketorolac and Vitreoretinal Surgery Ketorolac - Surgery | Phase 2 / Phase 3 | Completed | Emory University | 76 | 2006-11-01 | 2014-05-14 |
| CLAIR -FO: Clinical Trial of Ophthalmic Insert Mydriasert® Versus Reference Treatment Mydriasert®, phenylephrine and tropicamide eyedrops - Retinal Anomalies, Premature Birth | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 80 | 2006-01-01 | 2008-04-10 |
| Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation 1% tropicamide and 10% phenylephrine - Eye Diseases | Phase 3 | Completed | Khon Kaen University | 80 | 2004-12-01 | 2012-03-09 |
Mydriasis (10) · Dilatation, Pathologic (3) · Eye Diseases (2) · Miosis (2) · Cataract (1) · Corneal Endothelial Cell Loss (1) · Myopia (1) · Premature Birth (1) · Presbyopia (1) · Respiratory Insufficiency (1)
Eye Diseases (10) · Pathological Conditions, Signs and Symptoms (6) · Pathological Conditions, Anatomical (3) · Signs and Symptoms (3) · Nervous System Diseases (2) · Neurologic Manifestations (2) · Corneal Diseases (1) · Eye Manifestations (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Lens Diseases (1) · Obstetric Labor Complications (1) · Obstetric Labor, Premature (1) · Pathologic Processes (1) · Postoperative Complications (1)
Phenylephrine (3) · Tropicamide (3) · Ophthalmic Solutions (2) · Ketorolac (1) · Remifentanil (1)
Opus Genetics, Inc (3) · Eyenovia Inc. (2) · Assistance Publique - Hôpitaux de Paris (1) · Cairo University (1) · Corxel Pharmaceuticals (1) · Emory University (1) · Khon Kaen University (1) · Taejoon Pharmaceutical Co., Ltd. (1) · University of California, San Francisco (1)
United States (7) · China (1) · Egypt (1) · France (1) · South Korea (1) · Thailand (1)
Tsontcho Ianchulev, MD, MPH (2) · Charles Slonim, MD (1) · Gloria Sun (1) · Rachel Eshima McKay, MD (1) · Stephen J Kim, MD (1) · Yosanan Yospaiboon, M.D. (1)